Important Information for Regeneron Pharmaceuticals Investors: Deadline Reminder for Securities Class Action Lawsuit
New York, NY, January 29, 2025. Investors who purchased or acquired the securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023, and October 30, 2024, inclusive (the “Class Period”), are hereby reminded that the lead plaintiff deadline in a securities class action lawsuit is approaching. The Rosen Law Firm, a global investor rights law firm, is actively investigating the alleged securities fraud claims against the Company and Encourages investors to contact the firm before the deadline.
What is a Securities Class Action Lawsuit?
A securities class action lawsuit is a type of legal action where a large group of investors, known as the “class,” alleges that they have been harmed by the false or misleading statements made by a publicly-traded company (in this case, Regeneron Pharmaceuticals) and its executives or directors. The lead plaintiff is the representative of the class, and the lawsuit seeks to recover damages on behalf of all class members. If the lawsuit is successful, the damages are distributed to the class members.
Why Should I Care?
If you purchased Regeneron securities during the Class Period, you may be eligible to participate in the securities class action lawsuit and potentially recover your losses without paying any out-of-pocket fees or costs. The Rosen Law Firm is investigating allegations that Regeneron and certain of its executives or directors made false or misleading statements regarding the Company’s financial condition and business prospects.
How Will This Affect Me?
If the securities class action lawsuit is successful, investors who purchased Regeneron securities during the Class Period may be entitled to recover their losses. The exact amount of damages each investor may receive depends on the size of their investment and the outcome of the lawsuit. It’s important to note that past performance does not guarantee future results, and there is no guarantee that the lawsuit will be successful.
How Will This Affect the World?
The outcome of the securities class action lawsuit against Regeneron Pharmaceuticals could have significant implications for the biopharmaceutical industry and investor confidence in publicly-traded companies. If the lawsuit is successful, it may deter companies from making false or misleading statements about their financial condition and business prospects. Conversely, if the lawsuit is unsuccessful, it may embolden companies to continue making such statements.
What Should I Do Next?
If you purchased Regeneron securities during the Class Period and wish to join the securities class action lawsuit, you should contact The Rosen Law Firm before the lead plaintiff deadline on March 10, 2025. You may also wait and be represented by the firm if you choose to do so. The Rosen Law Firm will provide free consultations to potential class members and will help them determine whether they are eligible to recover damages.
Conclusion
Investors who purchased Regeneron Pharmaceuticals securities between November 2, 2023, and October 30, 2024, are reminded that they may be entitled to compensation without payment of any out-of-pocket fees or costs if the securities class action lawsuit against the Company is successful. The Rosen Law Firm is actively investigating the allegations of securities fraud and encourages investors to contact the firm before the lead plaintiff deadline on March 10, 2025.
- If you purchased Regeneron securities during the Class Period, you may be eligible to recover your losses.
- The Rosen Law Firm is investigating allegations of securities fraud against Regeneron Pharmaceuticals.
- The lead plaintiff deadline for the securities class action lawsuit is March 10, 2025.
- Contact The Rosen Law Firm for a free consultation.
